These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10091118)

  • 1. Predicting relative binding affinities of non-peptide HIV protease inhibitors with free energy perturbation calculations.
    McCarrick MA; Kollman PA
    J Comput Aided Mol Des; 1999 Mar; 13(2):109-21. PubMed ID: 10091118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
    Kar P; Lipowsky R; Knecht V
    J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calculation of relative differences in the binding free energies of HIV1 protease inhibitors: a thermodynamic cycle perturbation approach.
    Reddy MR; Varney MD; Kalish V; Viswanadhan VN; Appelt K
    J Med Chem; 1994 Apr; 37(8):1145-52. PubMed ID: 8164256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free energy perturbation studies on binding of A-74704 and its diester analog to HIV-1 protease.
    Rao BG; Murcko MA
    Protein Eng; 1996 Sep; 9(9):767-71. PubMed ID: 8888142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations.
    Hansson T; Aqvist J
    Protein Eng; 1995 Nov; 8(11):1137-44. PubMed ID: 8819979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Free energy component analysis for drug design: a case study of HIV-1 protease-inhibitor binding.
    Kalra P; Reddy TV; Jayaram B
    J Med Chem; 2001 Dec; 44(25):4325-38. PubMed ID: 11728180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design.
    Rutenber E; Fauman EB; Keenan RJ; Fong S; Furth PS; Ortiz de Montellano PR; Meng E; Kuntz ID; DeCamp DL; Salto R
    J Biol Chem; 1993 Jul; 268(21):15343-6. PubMed ID: 8340363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
    Aruksakunwong O; Wolschann P; Hannongbua S; Sompornpisut P
    J Chem Inf Model; 2006; 46(5):2085-92. PubMed ID: 16995739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimates of relative binding free energies for HIV protease inhibitors using different levels of approximations.
    Lee CY; Yang PK; Tzou WS; Hwang MJ
    Protein Eng; 1998 Jun; 11(6):429-37. PubMed ID: 9725621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.
    Pérez C; Pastor M; Ortiz AR; Gago F
    J Med Chem; 1998 Mar; 41(6):836-52. PubMed ID: 9526559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated molecular simulation based binding affinity calculator for ligand-bound HIV-1 proteases.
    Sadiq SK; Wright D; Watson SJ; Zasada SJ; Stoica I; Coveney PV
    J Chem Inf Model; 2008 Sep; 48(9):1909-19. PubMed ID: 18710212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An approach to rapid estimation of relative binding affinities of enzyme inhibitors: application to peptidomimetic inhibitors of the human immunodeficiency virus type 1 protease.
    Viswanadhan VN; Reddy MR; Wlodawer A; Varney MD; Weinstein JN
    J Med Chem; 1996 Feb; 39(3):705-12. PubMed ID: 8576913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empirical free energy calculations of human immunodeficiency virus type 1 protease crystallographic complexes. II. Knowledge-based ligand-protein interaction potentials applied to thermodynamic analysis of hydrophobic mutations.
    Verkhivker GM
    Pac Symp Biocomput; 1996; ():638-52. PubMed ID: 9390264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative binding free energies of peptide inhibitors of HIV-1 protease: the influence of the active site protonation state.
    Chen X; Tropsha A
    J Med Chem; 1995 Jan; 38(1):42-8. PubMed ID: 7837238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
    Lepsík M; Kríz Z; Havlas Z
    Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Examining methods for calculations of binding free energies: LRA, LIE, PDLD-LRA, and PDLD/S-LRA calculations of ligands binding to an HIV protease.
    Sham YY; Chu ZT; Tao H; Warshel A
    Proteins; 2000 Jun; 39(4):393-407. PubMed ID: 10813821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calculation of solvation and binding free energy differences between VX-478 and its analogs by free energy perturbation and AMSOL methods.
    Rao BG; Kim EE; Murcko MA
    J Comput Aided Mol Des; 1996 Feb; 10(1):23-30. PubMed ID: 8786412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Leonis G; Steinbrecher T; Papadopoulos MG
    J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.
    Nalam MN; Ali A; Altman MD; Reddy GS; Chellappan S; Kairys V; Ozen A; Cao H; Gilson MK; Tidor B; Rana TM; Schiffer CA
    J Virol; 2010 May; 84(10):5368-78. PubMed ID: 20237088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.